Role of brain lipid metabolism in Alzheimer's disease

脑脂质代谢在阿尔茨海默病中的作用

基本信息

  • 批准号:
    10532713
  • 负责人:
  • 金额:
    $ 60.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-03-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Both environmental and genetic factors involved in the disturbance of cholesterol metabolism have been suggested as risk factors for the development of Alzheimer's disease (AD). Accumulation of cholesterol has been observed in affected brain areas from AD patients and animals, and it is associated with region-specific loss of synapses. Elevated brain cholesterol causes cognitive deficits, amyloid-β (Aβ) production and aggregation, and tau pathology. Despite these observations, the mechanisms that govern brain cholesterol homeostasis and influence on neurons under AD-related pathological conditions remain elusive. In particular, the field lacks knowledge on the factors that are involved in the signaling pathways of neuronal cholesterol metabolism, related to the initiation and development of AD pathology. ATAD3A belongs to a new family of eukaryotic mitochondrial AAA-ATPases. ATAD3A regulates cholesterol homeostasis and trafficking via an unknown mechanism at the mitochondria-associated ER membrane (MAM), a specialized subdomain of the ER that has the features of a lipid raft and is rich in cholesterol and sphingomyelin. Our recent work demonstrated that ATAD3A, via pathological dimerization, showed a gain-of-function that caused neurodegeneration in Huntington's disease. We further observed an enhancement of ATAD3A oligomerization in AD neuronal culture, in AD transgenic mouse brains and in AD patient postmortem hippocampus, suggesting an aberrant activity of ATAD3A in the pathogenesis of AD. We developed a novel peptide inhibitor DA1 that binds to ATAD3A to block ATAD3A dimerization. Notably, sustained treatment with DA1 reduced APP level and amyloid load, attenuated neuro-inflammation and improved short-term spatial memory in 5XFAD transgenic mice. Further, our proteomic analysis suggests that blocking ATAD3A oligomerization by DA1 treatment mainly influenced the cholesterol metabolic pathway in AD mouse brains. The treatment in AD transgenic mice improved brain cholesterol turnover and did not affect brain phospholipids levels. Moreover, we showed that DA1 treatment reduced cholesterol burden and oxidative stress in neuronal cells stably expressing APP wt or mutant. These findings highlight ATAD3A oligomerization as a previously unidentified mechanism underlying brain cholesterol disturbance and neurodegeneration in AD. Our central hypothesis is that ATAD3A oligomerization mediates amyloid pathology, leading to neurodegeneration, by impairment of brain cholesterol metabolism. The overall goal of this application is to understand ATAD3A aberrant oligomerization-mediated neuropathology in AD, and to reveal a novel therapeutic target for AD. In Aim 1, we will determine the impact of ATAD3A oligomerization on brain cholesterol homeostasis, AD pathology and behavioral deficits in AD mice. In Aim 2, we will determine whether haplosufficiency of ATAD3A in AD mice restores brain cholesterol homeostasis and reduces AD pathology. In Aim 3, we will dissect the mechanistic links between ATAD3A oligomerization and disturbance in brain cholesterol homeostasis in AD.
环境和遗传因素均与胆固醇代谢紊乱有关 建议作为阿尔​​茨海默病(AD)发展的危险因素。胆固醇的积累有 在 AD 患者和动物受影响的大脑区域中观察到,它与区域特异性相关 突触丧失。脑胆固醇升高会导致认知缺陷、β-淀粉样蛋白 (Aβ) 产生和 聚集和 tau 病理学。尽管有这些观察结果,控制大脑胆固醇的机制 AD 相关病理条件下的稳态和对神经元的影响仍然难以捉摸。尤其, 该领域缺乏对参与神经元胆固醇信号传导途径的因素的了解 代谢,与 AD 病理的发生和发展有关。 ATAD3A 属于一个新家族 真核线粒体 AAA-ATP 酶。 ATAD3A 通过调节胆固醇稳态和运输 线粒体相关内质网膜(MAM)的未知机制,这是线粒体的一个专门亚结构域 ER具有脂筏的特征,富含胆固醇和鞘磷脂。我们最近的工作 证明 ATAD3A 通过病理二聚化表现出功能获得性,导致 亨廷顿病中的神经变性。我们进一步观察到 ATAD3A 寡聚化的增强 在 AD 神经元培养物、AD 转基因小鼠大脑和 AD 患者死后海马体中, 提示 ATAD3A 在 AD 发病机制中存在异常活性。我们开发了一种新型肽抑制剂 DA1 与 ATAD3A 结合以阻止 ATAD3A 二聚化。值得注意的是,持续使用 DA1 治疗可减少 5XFAD 中的 APP 水平和淀粉样蛋白负荷、减轻神经炎症并改善短期空间记忆 转基因小鼠。此外,我们的蛋白质组分析表明,通过 DA1 阻断 ATAD3A 寡聚化 治疗主要影响AD小鼠大脑中的胆固醇代谢途径。 AD的治疗 转基因小鼠改善了大脑胆固醇周转,但不影响大脑磷脂水平。而且, 我们发现 DA1 治疗可稳定降低神经元细胞中的胆固醇负担和氧化应激 表达APP wt或突变体。这些发现强调 ATAD3A 寡聚化是一种先前未鉴定的 AD 中脑胆固醇紊乱和神经变性的机制。我们的中心假设是 ATAD3A 寡聚化介导淀粉样蛋白病理学,通过损伤 脑胆固醇代谢。该应用程序的总体目标是了解 ATAD3A 异常 寡聚化介导的 AD 神经病理学,并揭示 AD 的新治疗靶点。在目标 1 中,我们 将确定 ATAD3A 寡聚化对脑胆固醇稳态、AD 病理学和 AD小鼠的行为缺陷。在目标 2 中,我们将确定 AD 小鼠中 ATAD3A 是否单倍充足 恢复大脑胆固醇稳态并减少 AD 病理。在目标 3 中,我们将剖析其机制 ADAD 中 ATAD3A 寡聚化与脑胆固醇稳态紊乱之间的联系。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

XIN QI其他文献

XIN QI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('XIN QI', 18)}}的其他基金

Mechanism of white matter pathology in Alzheimer's disease
阿尔茨海默病的白质病理机制
  • 批准号:
    10381841
  • 财政年份:
    2022
  • 资助金额:
    $ 60.38万
  • 项目类别:
Mechanism of white matter pathology in Alzheimer's disease
阿尔茨海默病的白质病理机制
  • 批准号:
    10553238
  • 财政年份:
    2022
  • 资助金额:
    $ 60.38万
  • 项目类别:
Regulation of CHCHD6 in Alzheimer's disease
CHCHD6 在阿尔茨海默病中的调控
  • 批准号:
    10461551
  • 财政年份:
    2022
  • 资助金额:
    $ 60.38万
  • 项目类别:
Role of brain lipid metabolism in Alzheimer's disease
脑脂质代谢在阿尔茨海默病中的作用
  • 批准号:
    10334516
  • 财政年份:
    2020
  • 资助金额:
    $ 60.38万
  • 项目类别:
Proteostasis dysregulation and alpha-synuclein
蛋白质稳态失调和 α-突触核蛋白
  • 批准号:
    10620658
  • 财政年份:
    2020
  • 资助金额:
    $ 60.38万
  • 项目类别:
Proteostasis dysregulation and alpha-synuclein
蛋白质稳态失调和 α-突触核蛋白
  • 批准号:
    10400854
  • 财政年份:
    2020
  • 资助金额:
    $ 60.38万
  • 项目类别:
Dynamin-related protein 1, neurodegeneration and Huntington's disease
动力相关蛋白 1、神经变性和亨廷顿病
  • 批准号:
    9285853
  • 财政年份:
    2014
  • 资助金额:
    $ 60.38万
  • 项目类别:
Dynamin-related protein 1, neurodegeneration and Huntington's disease
动力相关蛋白 1、神经变性和亨廷顿病
  • 批准号:
    8744411
  • 财政年份:
    2014
  • 资助金额:
    $ 60.38万
  • 项目类别:
Generating iPSC-derived Neurons to Explore Formation & Inhibition of Human Prions
生成 iPSC 衍生神经元以探索形成
  • 批准号:
    8824349
  • 财政年份:
    2014
  • 资助金额:
    $ 60.38万
  • 项目类别:
Dynamin-related protein 1, neurodegeneration and Huntington's disease
动力相关蛋白 1、神经变性和亨廷顿病
  • 批准号:
    8848902
  • 财政年份:
    2014
  • 资助金额:
    $ 60.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了